- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07469891
Фаза 1 исследования препарата PRT12396 у участников с выбранными миелопролиферативными новообразованиями
Фаза 1, открытое, многоцентровое исследование безопасности и эффективности препарата PRT12396 у участников с истинной полицитемией и миелофиброзом
This is a first-in-human, open-label, multi-center Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and myelofibrosis (MF), and to determine the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE[s]). The study consists of a dose-escalation phase followed by a dose-expansion phase to further evaluate selected dose level(s).
Обзор исследования
Статус
Условия
Вмешательство/лечение
Подробное описание
This first-in-human, open-label, multi-center Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and myelofibrosis (MF). Eligible MF populations include participants with intermediate-1, intermediate-2, or high-risk primary MF, as well as post-polycythemia vera MF or post-essential thrombocythemia MF, with evidence of disease burden based on splenomegaly.
The study is conducted in two parts:
Part 1 (dose escalation) evaluates escalating oral doses of PRT12396 to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE[s]).
Part 2 (dose expansion) enrolls additional participants at selected dose level(s) to further characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in the PV and MF populations.
Approximately up to 100 participants are planned for enrollment across both parts of the study.
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 1
Контакты и местонахождение
Контакты исследования
- Имя: Study Contact (Please Do Not Disclose Personal Information)
- Номер телефона: See Email
- Электронная почта: clinicaltrials@preludetx.com
Места учебы
-
-
South Australia
-
Adelaide, South Australia, Австралия, 5000
- Рекрутинг
- Royal Adelaide Hospital
-
-
Victoria
-
Clayton, Victoria, Австралия, 3168
- Рекрутинг
- Monash Health, Monash Medical Centre
-
-
Western Australia
-
Nedlands, Western Australia, Австралия, 6009
- Рекрутинг
- One Clinical Research
-
-
-
-
-
Barcelona, Испания, 08036
- Рекрутинг
- Hospital Clinic de Barcelona
-
Madrid, Испания, 28034
- Рекрутинг
- Hospital Universitario Ramon y Cajal
-
Madrid, Испания, 28041
- Рекрутинг
- Hospital Universitario 12 de Octubre
-
Valencia, Испания, 46010
- Рекрутинг
- Hospital Clínico Universitario de Valencia
-
-
-
-
-
Florence, Италия, 50134
- Рекрутинг
- Azienda Ospedaliero Universitaria Careggi
-
-
-
-
California
-
Los Angeles, California, Соединенные Штаты, 90095
- Рекрутинг
- UCLA Ronald Reagan Medical Center
-
Sacramento, California, Соединенные Штаты, 95817
- Рекрутинг
- University of California, Davis Comprehensive Cancer Center
-
-
Colorado
-
Denver, Colorado, Соединенные Штаты, 80218
- Рекрутинг
- Colorado Blood Cancer Institute
-
-
Florida
-
Coral Springs, Florida, Соединенные Штаты, 33065
- Рекрутинг
- BRCR Global - Coral Springs
-
Miami, Florida, Соединенные Штаты, 33136
- Рекрутинг
- Sylvester Comprehensive Cancer Center
-
Tampa, Florida, Соединенные Штаты, 33612
- Рекрутинг
- Moffitt Cancer Center
-
-
Michigan
-
Grand Rapids, Michigan, Соединенные Штаты, 49546
- Рекрутинг
- START Midwest, LLC
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Соединенные Штаты, 19107
- Рекрутинг
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Trials Office
-
-
Tennessee
-
Nashville, Tennessee, Соединенные Штаты, 37203
- Рекрутинг
- Tristar BMT
-
Nashville, Tennessee, Соединенные Штаты, 37203
- Рекрутинг
- Tennessee Oncology, PLLC - Investigational Drug Services
-
-
Texas
-
Houston, Texas, Соединенные Штаты, 77030
- Рекрутинг
- The University of Texas, MD Anderson Cancer Center
-
-
-
-
-
Nice, Франция, 06200
- Рекрутинг
- Nice University Medicâl Center (CHU Nice, Hôpital Archet 1)
-
Paris, Франция, 75010
- Рекрутинг
- Saint-Louis Hospital
-
Toulouse, Франция, 31059
- Рекрутинг
- Oncopole Claudius Regaud
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations (including contraception requirements), and other study procedures.
- Confirmed diagnosis of PV or MF according to WHO 2016 or revised ICC/WHO 2022 criteria
- Documented presence of a JAK2 V617 mutation
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Estimate life expectancy of ≥12 weeks per investigator assessment.
- Negative serum or urine pregnancy test and agree to use contraception or maintain true abstinence.
- Adequate organ function and bone marrow reserves (hematology, renal, and hepatic)
Exclusion Criteria:
- History of another malignancy within 3 years prior to enrollment, except for malignancy considered cured with low risk of recurrence.
- Clinically significant anemia due to nutritional deficiency or hemolytic disorders.
- Active or uncontrolled infection requiring systemic therapy or hospitalization.
- Any other medical or psychiatric conditions that, in the Investigator's judgment, would increase risk or interfere with study participation or interpretation of results.
- Clinically significant or uncontrolled medical conditions, including active infection or cardiovascular disease, that would increase risk or interfere with study participation.
- Unresolved toxicity Grade >1 from prior anticancer therapy, except for alopecia or peripheral neuropathy Grade ≤2.
- Pregnancy or breastfeeding
- Known sensitivity or contraindication to any component of study, or the excipients of study treatment.
- Prior systemic therapy for PV or MF, prior or planned allogeneic hematopoietic stem-cell transplantation, recent major surgery, prior splenectomy or prior splenic irradiation, or use of hematopoietic growth factors within protocol-defined washout periods.
- Use of strong or moderate cytochrome P450 (CYP) 3A4 inhibitor or inducer, sensitive CYP3A substrates with narrow therapeutic range, or acid-reducing agents that cannot be discontinued prior to study treatment.
- Participation in another interventional clinical study.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Нерандомизированный
- Интервенционная модель: Последовательное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: PRT12396: MF
Participants with myelofibrosis receive PRT12396, an investigational oral capsule, administered twice daily. The study includes a dose-escalation followed by dose-expansion at the recommended dose for expansion (RDE) |
PRT12396 is an investigational oral capsule administered twice daily at the assigned dose level or RDE. Capsules are swallowed whole with water and may be taken one hour before or two hours after meals. |
|
Экспериментальный: PRT12396: PV
Participants with polycythemia vera receive PRT12396, an investigational oral capsule, administered twice daily. The study includes a dose-escalation followed by dose-expansion at the recommended dose for expansion (RDE) |
PRT12396 is an investigational oral capsule administered twice daily at the assigned dose level or RDE. Capsules are swallowed whole with water and may be taken one hour before or two hours after meals. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Dose limiting toxicity (DLT) of PRT12396
Временное ограничение: Through cycle 1 (4 weeks)
|
Incidence of dose limiting toxicities, defined according to protocol-specified criteria |
Through cycle 1 (4 weeks)
|
|
Incidence and severity of Adverse events
Временное ограничение: Through study completion, an average of 2 years
|
Incidence and severity of treatment-emergent adverse events (AEs), graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 6.0 |
Through study completion, an average of 2 years
|
|
Adverse Events Leading to Dose Modifications or Discontinuation
Временное ограничение: Through study completion, an average of 2 years
|
Incidence of AEs leading to dose reductions, dose interruptions, treatment discontinuations, and clinically significant laboratory abnormalities |
Through study completion, an average of 2 years
|
|
Maximum tolerated dose (MTD) and Recommended Dose(s) for Expansion (RDE[s]) of PRT12396
Временное ограничение: Through study completion, an average of 2 years
|
Determination of the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE[s]) based on evaluation of DLTs, safety, and tolerability data |
Through study completion, an average of 2 years
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Hematologic Response Rate (PV)
Временное ограничение: Through study completion, an average of 2 years
|
Proportion of participants with polycythemia vera (PV) achieving best overall hematologic response (complete hematologic response or partial hematologic response) from the overall response assessments by Investigator |
Through study completion, an average of 2 years
|
|
Duration of Hematologic Response (PV)
Временное ограничение: Through study completion, an average of 2 years
|
Duration of hematologic response in PV participants, defined as the time from first documented response (best overall hematologic response) to disease progression or death, whichever comes first |
Through study completion, an average of 2 years
|
|
Hematocrit Control Without Phlebotomy Requirements (PV)
Временное ограничение: Through study completion, an average of 2 years
|
Proportion of PV participants achieving and maintaining hematocrit control without phlebotomy, time to first phlebotomy, and frequency of phlebotomy |
Through study completion, an average of 2 years
|
|
Spleen Response (MF)
Временное ограничение: Through study completion, an average of 2 years
|
Assessment of spleen response including proportion achieving protocol-specified reduction in spleen volume, time to spleen response, duration of spleen response, and reduction in palpable spleen length |
Through study completion, an average of 2 years
|
|
Change from Baseline in Hemoglobin (MF)
Временное ограничение: Through study completion, an average of 2 years
|
Change from baseline in hemoglobin levels in MF participants |
Through study completion, an average of 2 years
|
|
Change from Baseline in Platelet Count (MF)
Временное ограничение: Through study completion, an average of 2 years
|
Change from baseline in platelet count in MF participants |
Through study completion, an average of 2 years
|
|
Change from Baseline in Absolute Neutrophil Count (MF)
Временное ограничение: Through study completion, an average of 2 years
|
Change from baseline in absolute neutrophil count in MF participants |
Through study completion, an average of 2 years
|
|
Transfusion Independence (MF)
Временное ограничение: Through study completion, an average of 2 years
|
Proportion achieving transfusion independence and duration of transfusion independence as defined by protocol criteria |
Through study completion, an average of 2 years
|
|
Maximum Observed Plasma Concentration (Cmax)
Временное ограничение: Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
Maximum observed plasma concentration will be calculated using non-compartmental analysis |
Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
|
Time To Maximum Concentration (Tmax)
Временное ограничение: Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
Time to maximum concentration will be calculated using non-compartmental analysis |
Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
|
Area under the plasma concentration versus time curve (AUC)
Временное ограничение: Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
Area under the plasma concentration-time curve will be calculated using non-compartmental analysis |
Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
|
Terminal Elimination Half-life (T1/2)
Временное ограничение: Cycle 1 Day 1
|
Terminal elimination half-life will be calculated using non-compartmental analysis |
Cycle 1 Day 1
|
|
Steady State Trough Concentrations
Временное ограничение: Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
Steady state trough concentrations will be calculated using non-compartmental analysis |
Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
|
Clearance
Временное ограничение: Cycle 1 Day 1
|
Clearance will be calculated using non-compartmental analysis |
Cycle 1 Day 1
|
|
Accumulation
Временное ограничение: Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
Accumulation will be calculated using non-compartmental analysis |
Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
|
Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)
Временное ограничение: Through study completion, an average of 2 years
|
Patient-reported outcomes assessed using the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS), evaluated as change from baseline at protocol-specified time points. The MPN SAF TSS is a validated questionnaire in which individual symptoms are scored using a numeric rating scale ranging from 0 to 10, with 0 indicating no symptoms and 10 indicating the worst imaginable symptoms; higher scores indicate greater symptom severity. |
Through study completion, an average of 2 years
|
|
Patient Global Impression of Change (PGI-C)
Временное ограничение: Through study completion, an average of 2 years
|
Participant reported outcomes assessed using the Patient Global Impression of Change (PGI-C), evaluated at protocol-specified time points. The PGI C is a global assessment scale in which participants rate their overall change in condition since baseline using a 7 point ordinal scale ranging from "very much improved" to "very much worse," with lower scores indicating improvement and higher scores indicating worsening of symptoms. |
Through study completion, an average of 2 years
|
Соавторы и исследователи
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- PRT12396-01
- 2026-525484-40-00 (Ктис)
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .